Highest-materiality recent filing
Covista Q3 revenue up 4.5%, enrollment over 100k; raises FY2026 revenue and EPS guidance
Revenue $487M (+4.5% YoY); adjusted EPS $1.98 vs $1.92; GAAP EPS $1.20 vs $1.59.
Covista targets 7-10% revenue CAGR, >120k enrollment by FY2029 in new strategy
Financial targets through FY2029: revenue CAGR 7-10%, adjusted EPS CAGR 10-14%, enrollment >120,000.
Covista enters $510M term loan refinancing, redeems $405M senior notes
New $510M 2026 Term Loans issued under amended credit agreement, maturing March 2, 2033.
Covista unveils 'Purpose at Scale' 3-year plan; FY26 reaffirmed, ticker to CVSA
Introduces 'Purpose at Scale' strategy for FY27-29 targeting revenue growth 6-11% and adj. EPS growth 9-16% annually.
Adtalem rebrands as Covista, ticker CVSA; launches research platform and investor day
Name changed from Adtalem Global Education to Covista Inc. effective Feb 5, 2026; NYSE ticker changes to CVSA effective Feb 24.
Adtalem completes $150M buyback, authorizes new $750M repurchase program
Completed $150M accelerated share repurchase program; repurchased 1.6M shares.
Adtalem FY2025 revenue $1.79B (+12.9%), adj EPS $6.67 (+33%); FY2026 guidance $7.60-$7.90 adj EPS
Q4 revenue $457.1M (+11.5%), total enrollment 91,780 (+10.2% YoY).
Adtalem Q3 FY2025 EPS $1.59 ($1.92 adj.), revenue $466.1M +12.9%; raises FY guidance
Revenue $466.1M (+12.9% YoY); diluted EPS $1.59 (adj. $1.92, +28% YoY); net income $60.8M.
Adtalem authorizes $150M new buyback; completes $300M prior program, returns $763M since 2022
Board authorized $150M share repurchase program, expiring May 2028.
Adtalem Q2 FY2025 EPS $1.98 ($1.81 adjusted), revenue up 13.9%, guidance raised
Revenue $447.7M (+13.9% YoY); GAAP net income $75.9M ($1.98 diluted EPS).
Adtalem CEO Steve Beard elected Chairman; Q1 enrollment up 11.2% to 90,000+
Steve Beard, President and CEO, unanimously elected Chairman of the Board effective Nov. 13, 2024.
Adtalem Q1 FY2025: Revenue up 13.2%, adj. EPS $1.29 (+38.7% YoY); raises FY guidance
Revenue $417.4M (+13.2% YoY); net income $46.2M vs $10.6M prior year; adj. EPS $1.29 vs $0.93.
Adtalem Q4 rev $409.9M (+12.4% YoY); FY25 EPS guidance $5.60-$5.85 above prior projections
FY24 diluted EPS $3.39; adjusted EPS $5.01 (+19% YoY). Revenue $1,584.7M (+9.2% YoY).
Adtalem Q3 revenue up 11.8% YoY; adjusted EPS $1.50, raises FY2024 guidance
Revenue $412.7M (+11.8% YoY); total enrollment 85,809 (+7.8% YoY).
Total enterprise enrollment up 6% YoY as of Dec 31, 2023; Chamberlain up 7%, Walden up 8%.
Adtalem Q2 revenue +8.4% to $393.2M, raises FY guidance; short seller report disclosed
Revenue $393.2M (+8.4% YoY); total enrollment 81,772 (+6.2%); Chamberlain enrollment +6.6%, Walden +7.9%.
On November 13, 2024, the Board of Directors (the “Board”) of Adtalem Global Education Inc. (“Adtalem” or “the Company”) unanimously elected Stephen W. Beard, Adtalem’s President and Chief Executive Officer, as Chairman of the Board effective immediately.
Mr. Malafronte will continue to serve on the Board as Lead Independent Director, Chair of the Compensation Committee, and a member of the Academic Quality Committee.
reporting that Dr. John Danaher President, Medical & Veterinary was leaving Adtalem effective September 15, 2023.
The Adtalem Board of Directors (the “Board”) has appointed Dr. Betty Vandenbosch as an independent member of Adtalem’s Board effective January 8, 2024
Max materiality 0.80 · Median 0.65 · Most common event earnings